Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors at 3 institutions in 2 countries.
Hai-Feng ZhangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.ORCID 0000-0001-8215-1870
Alberto DelaidelliDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.
Sumreen JavedFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
Busra TurguDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.ORCID 0000-0002-0207-1115
Taylor MorrisonDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z1L3, Canada.ORCID 0009-0001-5319-8669
Christopher S HughesDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.ORCID 0000-0002-6980-4459
Xiaqiu YangDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z1L3, Canada.
Manideep PachvaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.
Michael M LizardoDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.
Gurdeep SinghDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z1L3, Canada.ORCID 0000-0003-2519-0456
Jennifer HoffmannDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-5202-0893
Yue Zhou HuangDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, BC V5Z1L3, Canada.ORCID 0000-0002-3381-9640
Khushbu PatelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-3269-7442
Rawan ShraimDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Gregg B MorinCanada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z4S6, Canada.ORCID 0000-0001-8949-4374
Samuel AparicioDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.
Daniel MartinezDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-4723-9989
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-8088-7929
Kristopher R BosseDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-1424-2858
Karla C WilliamsFaculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-2954-2869
Poul H SorensenDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T1Z4, Canada.ORCID 0000-0001-7447-2199
BC Cancer Agency · CAChildren's Hospital of Philadelphia · USUniversity of British Columbia · CA
Funding
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1M
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastomaK08CA230223 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI BOSSE, KRISTOPHER R · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA230223NCI NIH HHS U54 CA232568
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
NeuroblastomaSecretomeCell SurvivalHumansN-Myc Proto-Oncogene ProteinMYCN protein, humanN-Myc Proto-Oncogene Protein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in · full record | OpenQuestion